Report Date: Monday, July 27, 2026 (after market close) | Event: 2026Q2 Earnings Call
BRO shares have had a brutal twelve months, falling from roughly $109 last July to the high-$60s today — including a sharp post-earnings drop after Q2 2025 results, a steep autumn/winter slide that took the stock into the mid-$50s by May 2026, and only a partial rebound into the $65-$70 range over the past two months. Sentiment soured further just weeks before this report: Morgan Stanley cut BRO to Underweight from Equalweight on July 6, 2026, lowering its price target to $55 from $60, citing "a visible reset in organic growth, a softer pricing cycle, and heavier Florida and property sensitivity at this point in the cycle," along with rising middle-market competition. Other shops remain more constructive — MarketBeat's consensus target sits near $78.63, and one algorithmic model pegs fair value around $71.50 — leaving the Street split on whether the growth deceleration is cyclical or structural. That divergence sets up Q2 as a pivotal print: investors need proof that the sequential organic-growth improvement management promised in Q1 is actually materializing.
Wall Street models roughly $1.72 billion in revenue (about +34% y/y, driven almost entirely by the Accession/Risk Strategies acquisition) and adjusted EPS near $1.08–$1.09 (up ~5-6% y/y). BRO has beaten consensus EPS in each of the trailing four quarters (including a $1.39 vs. $1.36 beat last quarter), so the bar for a "beat" is arguably lower than the bar for reassuring organic-growth commentary and margin durability.
Q1 total revenue grew 35.4% to $1.9 billion, but organic revenue growth was flat year-over-year, with organic growth including contingent commissions up 2.2%. Adjusted EBITDAC margin expanded 40 bps to 38.5%, and adjusted diluted EPS grew 7.8% to $1.39. Management flagged several specific, quantifiable headwinds: roughly 100 bps of organic drag from a prior-year flood-claims processing comparison, CAT property rates falling "down 15% to 35%" in E&S placements, a pharmacy-consulting business transitioning from a volume-based to a PEPM fee model (expected to cost 50–100 bps of Retail organic growth over the next couple of quarters), and continued bleed from the Howden litigation, where lost annualized revenue grew from $23 million to $31 million.
1. Does organic growth actually inflect higher, as guided — or does the "heavy property quarter" dynamic bite? Management explicitly told investors that Q2 is a heavier CAT-property placement quarter for Specialty Distribution, and guided to "relatively flat organic growth, excluding contingents in Q2" for that segment, with improvement expected only in the back half as the acquired "180" casualty-weighted business rolls into the organic base. For Retail, they promised "modest organic growth improvement each quarter this year as compared to the first quarter," capped at roughly 2.5% by year-end. When directly pressed on whether Q2 could see sequential deterioration given the property-heavy mix, CFO Andy Watts held the line that the improvement trajectory still holds. This guidance will be tested directly by tomorrow's numbers.
2. Contingent commissions — the swing factor for margins. Contingents surged $54 million in Q1 (including $22 million from Accession), and management raised its full-year outlook, telling analysts they now "anticipate that our contingent commissions for the entire company will be up this year" versus a prior expectation of a modest decline, given how much upside came through in Q1. Since contingents run counter-cyclically to E&S property softness (profitable underwriting pays out more as rates fall), continued strength here would validate management's "stability" narrative — but investors should watch for any moderation, since some of Q1's contingent benefit reflected one-time prior-period accrual true-ups.
3. CAT property rate trajectory and any hurricane-season variables. Management guided E&S property rates to remain under pressure "like they were in the first quarter," while flagging that late-quarter dynamics could shift materially depending on carrier/MGA aggressiveness or an actual wind event. Given BRO's above-average Florida/coastal concentration — highlighted as a specific risk by Morgan Stanley's downgrade — commentary on how much further CAT rates have fallen (previously down 15-35%) and the state of summer wind-season underwriting appetite will be closely parsed.
4. Accession integration — synergies, margin drag, and segment mix. The $30–$40 million EBITDA synergy target for 2026 from the Accession (Risk Strategies) deal is a key deliverable; management said integration activities were "on track" as of Q1. Watch for: (a) confirmation synergies remain on pace; (b) the Retail EBITDAC margin, which fell 130 bps in Q1 largely due to Accession's different seasonal profit-weighting versus legacy Brown & Brown; and (c) further detail on the new blended regional/local sales model combining legacy Risk Strategies and Brown & Brown middle-market playbooks, which management believes will drive higher net-new business as it matures.
5. Howden litigation — is the bleed decelerating? The lost-business figure grew from $23 million to $31 million of annualized revenue by the end of Q1, tied to roughly 275 departed employees and an active Massachusetts TRO. Management wouldn't quantify a deceleration but flagged the TRO's restrictions as a mitigating factor. Any update on the pace of losses — or expansion of legal actions into other states — is a swing factor for Retail organic growth optics.
6. Employee benefits and pharmacy dynamics. Medical cost trend (up 8-10%) and pharmacy cost trend (up over 10%) remained elevated in Q1, a tailwind for BRO's benefits consulting/brokerage revenue even as it pressures customers. The pharmacy-consulting revenue model transition (volume-to-PEPM) is a known, quantified drag through mid-year that should start reversing "towards the end of the year," per guidance.
7. Capital allocation and balance sheet. BRO generated $262 million of operating cash flow in Q1 (cash conversion ~14% of revenue, down slightly y/y due to Accession integration costs and higher earn-out payments) and repurchased $250 million of stock in the quarter alone ($350 million over the trailing six months, cutting share count ~1.4%). With leverage elevated post-Accession (current + long-term debt near $7.8 billion) and 337 million diluted shares outstanding (versus 285 million a year ago), expect continued emphasis on debt paydown alongside buybacks, dividends (raised 10% y/y to $0.165/share), and disciplined tuck-in M&A.
8. Tax rate. The effective tax rate ticked up to 22.8% in Q1 from 21.8%, driven by state taxes, and CFO Andy Watts indicated it's "probably fair" to expect that higher rate to persist through 2026 — a modest but real drag on GAAP/adjusted EPS comparisons.
This print is less about the headline beat-or-miss (BRO has a strong beat streak and low bar on EPS) and more about credibility of the guided organic-growth acceleration amid a Florida/CAT-property-heavy Q2, the trajectory of the Howden employee-poaching litigation, and whether Accession integration synergies and contingent-commission strength can keep offsetting a genuinely softer property pricing cycle. With the stock already down sharply and a fresh Underweight rating from Morgan Stanley on the tape, the market has priced in real deceleration — meaning even an in-line quarter with confident, specific commentary on H2 organic growth and Accession synergy delivery could be read as a relief, while any signs that the "sequential improvement" framework is slipping would likely compound the recent negative momentum.